The FDA has delayed its decision on Lilly's Alzheimer’s drug, Donanemab, seeking more data on its efficacy and safety. Donanemab aims to slow cognitive decline in Alzheimer's patients by targeting amyloid plaques in the brain. This postponement... highlights the complexity of approving treatments for Alzheimer’s Disease, emphasizing the need for thorough evaluation to ensure patient safety.
Quality assurance is the top priority of ProvenExpert's terms of use and evaluation guidelines.
However, should you feel that a review is in violation of our guidelines, you can submit a request to have the review assessed by the ProvenExpert quality assurance team by using the following contact form.
Send email to reviewer
* Required fields
You have already posted this review on . Posting again might create duplication.
Continue?